Viral Disease
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Viral Disease is a moderately active landscape with 55 programs across 19 companies. The most active players are Frontier Biotechnologies Inc., Gilead, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 48 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Frontier Biotechnologies Inc.
1 program
Gilead
8 programs
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
4 programs
GSK
4 programs
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
4 programs
Glaxo Dba Glaxosmithkline
3 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
96%
Small molecule
53 of 55 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 55 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.
Analysis
Trial Status
4
clinical trials
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)